Sargent Bickham Lagudis LLC Axsome Therapeutics, Inc. Transaction History
Sargent Bickham Lagudis LLC
- $1.22 Billion
- Q4 2022
A detailed history of Sargent Bickham Lagudis LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 220 shares of AXSM stock, worth $27,893. This represents 0.0% of its overall portfolio holdings.
Number of Shares
220
Previous 220
-0.0%
Holding current value
$27,893
Previous $10,000
60.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AXSM
# of Institutions
352Shares Held
36.3MCall Options Held
1.77MPut Options Held
1.16M-
Rtw Investments, LP New York, NY4.05MShares$514 Million5.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.9MShares$495 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$418 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA1.47MShares$186 Million24.98% of portfolio
-
Bvf Inc San Francisco, CA1.39MShares$176 Million4.4% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $5.44B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...